Apx-343A
Advanced Solid Tumor (Phase 1)
Aptabio Therapeutics, Inc.Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
9 Active assets in the Advanced Solid Tumor (Phase 1) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nhwd-870 Zhejiang Wenda Pharma Technology LTD. | Phase 2 | CCC |
Imm-6-415 Immuneering Corporation | Phase 1/2 | CCC |
an8025 is a multifunctional antibody fusion protein Adlai Nortye Biopharma Co., Ltd. | Phase 1 | CC |
ep102 Epics Therapeutics | Phase 1 | CC |
Pembrolizumab Aptabio Therapeutics, Inc. | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Apx-343A is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →